

Economics

October ECT: Post-GST Durables Retreat

Economics | New Zealand

Key Points:

- Total retail spending on electronic cards rose 0.8%mom for October (5.6%yoy). However, excluding motor vehicle related spending core ECT spending was flat.
- The October ECT results incorporate the impact of both a higher rate of GST (12.5% to 15%) and also personal tax cuts. It is difficult to therefore decipher the relative impacts of both. Our initial thoughts are that the impact of tax changes has been relatively muted overall.
- However, the sectoral impact is more noticeable. Fuel retailing and consumables rose 8.4%mom and 2.4%mom respectively. We suspect this is largely price related as all the GST increase is passed on. On the other hand, durables spending retreated 6.0%mom - a pull-back from the 4.1%mom pre-GST spend up in September.
- Looking forward, with the labour market showing signs that it has turned we expect household consumption to continue a gradual recovery over 2011. However, headwinds remain, particularly a weak housing market.
- Our monetary policy views remain unchanged. That is, we expect the RBNZ to resume tightening in March next year.

Economist: Philip Borkin
+64 9 357 3206
philip.borkin@gs.co.nz

Key Data

ECT	Oct-10		Sep-10	
	mom	yoy	mom	yoy
Monthly Nominal				
Total	0.8%	5.6%	1.7%	4.5%
Core	0.0%	4.8%	1.5%	4.6%

Source: Statistics NZ

Soft underlying spending on post-GST durables retreat

Total retail spending on electronic cards rose 0.8%mom in October. This follows a 1.7%mom increase in September taking annual growth to 5.6%yoy. Excluding motor vehicle related spending, core ECT spending was flat following a 1.5%mom increase in September. Nevertheless annual growth of 4.8%yoy for core ECT spending is the strongest since January 2008.

Figure 1: Annual core ECT spending growth strongest since January 2008





Figure 2: Extent of spending recovery varies from data source however



The October ECT results incorporate the impact of both a higher rate of GST (12.5% to 15%) and also personal tax cuts. It is difficult to therefore decipher the relative impacts of both. *Ceteris paribus*, the higher rate of GST would have boosted the value of transactions in the month given higher prices. However, there are a number of factors that need to be taken into account. These include: 1) whether all the GST impact was passed on and the extent of discounting that retailers are still applying to drive turnover; 2) whether the underlying volume of spending was impacted by higher disposable incomes; and 3) whether there was any payback from a pre-GST spend-up evident in September. Our initial thoughts are that the impact of GST and personal income tax changes has been relatively muted overall.

Some may emphasise that with the number of ECT retail transactions up 5.9%yoy (6.7%yoy for core), this indicates a better spending backdrop. While this may indeed be the case, we are hesitant to come to that conclusion yet given that the volume data has an inherent bias given spending on electronic cards has been gaining a higher proportion of total retail spending and the value per transaction has generally been on a downward trend (figure 4).

While the impact of the GST change is unclear on the headline figures, it appears to have had a bigger impact on certain sectors. Fuel retailing rose 8.4%mom (seasonally adjusted) and consumables rose 2.4%mom. We suspect all of the GST increase will have been passed onto petrol and food prices. However, durables spending fell 6.0%mom - a pull-back from the 4.1%mom pre-GST spend up in September.

Figure 3: Durables spending impacted by post-GST hangover





Figure 4: Interpretation of ECT volume figures need to account for a lower mean transaction value



Looking forward (and putting monthly volatility aside), with the labour market showing signs that it has turned (ignoring data quality issues) we expect household consumption to continue a gradual recovery over 2011. However, with the housing market remaining weak, farm profitability squeezed (despite high prices) and balance sheet repair ongoing, we doubt consumers will come roaring out of the blocks any time soon.

Our monetary policy views remain unchanged. That is, we expect the RBNZ to resume tightening in March next year.

I, Philip Borkin, hereby certify that all of the views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in this report.

Disclosures of Interest

Important Notice - Nz:

New Zealand - Research Important Notice

See company-specific regulatory disclosures for any of the following disclosures required as to companies referred to in the report: manager or co manager in a pending transaction; financial advisor in a strategic corporate transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; market making and/or specialist role.

The following are additional required disclosures: Ownership and Material Conflicts of Interest: Goldman Sachs & Partners New Zealand Limited ("Goldman Sachs & Partners New Zealand") policy prohibits its analysts, assistant analysts and their respective associates owning securities of any company in the analyst's area of coverage. Analyst compensation: Analysts are paid in part based on the profitability of Goldman Sachs & Partners New Zealand which includes corporate advisory and financing revenues. Distribution of recommendations: See the distribution of recommendations disclosure on the following page.

Compendium Report

Please see disclosures at <http://www.gs.com.au/Disclosures>. Disclosures applicable to companies included in this compendium report can be found in the latest relevant published research.

Global Product; Distributing Entities

This report has been prepared by the Goldman Sachs & Partners New Zealand Research Division for distribution to clients of affiliates of Goldman Sachs & Partners New Zealand and pursuant to certain contractual arrangements to clients of affiliates of The Goldman Sachs Group, Inc. (Group) (Collectively, Group and its affiliates, "GS").

Group owns 45% of the ordinary shares of Goldman Sachs & Partners Australia Group Holdings Pty Ltd, the ultimate holding company of Goldman Sachs & Partners New Zealand. Research views, investment opinions and recommendations published by Goldman Sachs & Partners New Zealand are developed independently from those published by the Goldman Sachs Global Investment Research Division.

This research is disseminated in Australia by Goldman Sachs & Partners Australia Pty Ltd (ABN 21 006 797 897); in Canada by Goldman Sachs Canada Inc. regarding Canadian equities and by Goldman Sachs & Co. (all other research); in Germany by Goldman Sachs & Co. oHG; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs & Partners New Zealand Limited; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman, Sachs & Co. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom and European Union. Persons who would be categorized as private customers in the United Kingdom, as such term is defined in the rules of the Financial Services Authority, should read this material in conjunction with the last published reports on the companies mentioned herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risk warnings is available from the offices of Goldman Sachs International on request. Unless governing law permits otherwise, you must contact a Goldman Sachs entity in your home jurisdiction if you want to use Goldman Sachs & Partners New Zealand's or GS's services in effecting a transaction in the securities mentioned in this material.

European Union: Goldman Sachs International, authorised and regulated by the Financial Services Authority, has approved this research in connection with its distribution in the European Union and United Kingdom; Goldman, Sachs & Co. oHG, regulated by the Bundesanstalt fuer Finanzdienstleistungsaufsicht, may also be distributing research in Germany.

General Disclosures

This research is for clients only, as stated above. Other than disclosures relating to Goldman Sachs & Partners New Zealand, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than some industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs & Partners New Zealand and/or its affiliates conduct a global full-service, integrated corporate advisory and financing, investment management, and brokerage business. We have corporate advisory, corporate finance and other business relationships with a substantial percentage of the companies covered by our Investment Research Division.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, our proprietary trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

Goldman Sachs & Partners New Zealand and our affiliates, officers, directors, and employees, excluding equity analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors.

In producing research reports, members of Goldman Sachs & Partners New Zealand Investment Research may attend site visits and other meetings hosted by the issuers the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs & Partners New Zealand considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting.

Our research is disseminated primarily electronically, and, in some cases, in printed form. Electronic research is simultaneously available to all clients.

Disclosure information is also available at <http://www.gs.com.au/Disclosures> or from Research Compliance, Level 42, 1 Farrer Place Sydney NSW 2000.

Investment Adviser & Broker Disclosure Statement

The disclosure statement for Goldman Sachs & Partners New Zealand and your adviser is available on request and free of charge. Please contact your adviser to obtain a copy.

Research Analyst Certification

Each equity and strategy research report excerpted herein was certified under Reg AC by the analyst primarily responsible for such report as follows: I, <Name of Analyst>, hereby certify that all of the views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Copyright 2010 Goldman Sachs & Partners New Zealand Limited.

No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of Goldman Sachs & Partners New Zealand.

Goldman Sachs is a registered trade mark of Goldman, Sachs & Co.

New Zealand - Research Recommendation Definitions

Sell (S)	Stock is expected to underperform the NZSX 50 Index for 12 months
Hold (H)	Stock is expected to perform in line with the NZSX 50 Index for 12 months
Buy (B)	Stock is expected to outperform the NZSX 50 Index for 12 months

Other Definitions

NR	Not Rated. The investment rating has been suspended temporarily. Such suspension is in compliance with applicable regulations and/or Goldman Sachs & Partners New Zealand Limited ("GS&PNZ") policies in circumstances when GS&PNZ and/or, our affiliate, Goldman Sachs & Partners Australia Pty Ltd ("GS&PA") is acting in an advisory capacity in a merger or strategic transaction involving the company and in certain other situations.
CS	Coverage Suspended. GS&PNZ has suspended coverage of this company.
NC	Not Covered. GS&PNZ does not cover this company.

Target Price

Analysts set share price targets for individual companies based on a 12 month horizon. These share price targets are subject to a range of company specific and market risks. Target prices are based on a methodology chosen by the analyst as the best predictor of the share price over the 12 month horizon.

Research Criteria Definitions

The above recommendations are primarily determined with reference to the recommendation criteria outlined below. Analysts can introduce other factors when determining their recommendation, with any material factors stated in the written research where appropriate. Each criterion is clearly defined for the research team to ensure consistent consideration of the relevant criteria in an appropriate manner.

Industry Structure:	Based on GS&PNZ industry structure ranking. All industries relevant to the New Zealand equity market are ranked, based on a combination of Porter's Five Forces of industry structure as well as an industry's growth potential, relevant regulatory risk and probable technological risk. A company's specific ranking is based on the proportion of funds employed in particular industry segments, aggregated to determine an overall company rating, adjusted to reflect a view of the quality of a company's management team.
EVA™ Trend: ¹	EVA™ trend forecast for coming 2 years. Designed to reflect "turnaround stories" or to highlight companies GS&PNZ analysts believe will allocate capital poorly in the estimated timeframe.
Earnings Momentum:	The percentage change in the current consensus EPS estimate for the stock (year 1) over the consensus EPS estimate for the stock 3 months ago. Stocks are rated according to their relative rank, effectively making it a market relative measure.
Catalysts:	A qualitative and quantitative assessment of a company's long term catalysts that the analyst believes should be considered and possibly recognised by the market.
Price/Valuation:	The premium or discount to base case DCF valuation at which the stock is trading relative to the average premium or discount across the market.

For Insurers

ROE Trend: ¹	ROE is used as a proxy for EVA™. Rating takes into account the expected level and trend of ROE over the next 2 years.
Balance Sheet:	Analyst's assessment of the quality and strength of the insurer's balance sheet, including conservatism of provisioning, sufficiency of capital, and quality of capital.

For REITs

Strategy:	Used instead of industry structure as many REIT investors are intra rather than inter sector focussed.
EPU Growth:	Ranking of Earnings Per Unit growth relative to other listed Real Estate Investment Trusts. Used instead of EVA™ Trend.
Yield:	Yield relative to the REIT sector average. Used instead of Earnings Momentum.

For Australian Companies

Relevant Index:	If a research report is published by GS&PA, the recommendation of a company or trust is based on their performance relative to S&P/ASX 200 Index (Gross) and not the NZSX 50 Index.
-----------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

¹ EVA™ is a registered trademark of the U.S. consultancy firm Stern Stewart

Distribution of Recommendations – as at 30 September 2010

Recommendation	Overall	Corporate relationship* in last 12 months
Sell	7%	0%
Hold	57%	58%
Buy	36%	42%

* No direct linkage with overall distribution as the latter relates to the full GS&PA/GS&PNZ coverage (>250 companies). The above table combines the corporate relationships and recommendations of both GS&PA and GS&PNZ.